Table 2.
Soluble protein | Treatment arma | Median PFS (months) | HR (95 % CI) | Log-rank P | |
---|---|---|---|---|---|
<Median [protein] | ≥Median [protein] | ||||
VEGF-A | Sunitinib | 13.7 | 7.8 | 2.55 (1.19–5.48) | 0.0059 |
IFN-α | 7.8 | 3.9 | 1.35 (0.805–2.27) | 0.248 | |
VEGF-C | Sunitinib | 13.7 | 11.1 | 1.42 (0.779–2.59) | 0.242 |
IFN-α | 5.1 | 7.8 | 1.12 (0.619–2.01) | 0.713 | |
sVEGFR-3 | Sunitinib | 21.7 | 10.9 | 2.40 (1.13–5.11) | 0.0104 |
IFN-α | 5.4 | 3.9 | 1.16 (0.688–1.95) | 0.582 | |
IL-8 | Sunitinib | 21.7 | 12.4 | 1.20 (0.685–2.1) | 0.524 |
IFN-α | 7.8 | 2.6 | 1.84 (1.055–3.47) | 0.0472 |
Plasma protein | Treatment arma | Median OS (months) | HR (95 % CI) | Log-rank P | |
---|---|---|---|---|---|
<Median [protein] | ≥Median [protein] | ||||
VEGF-A | Sunitinib | NR | 21.8 | 2.60 (1.22–5.53) | 0.0043 |
IFN-α | 26.6 | 12.8 | 1.49 (0.903–2.45) | 0.11 | |
VEGF-C | Sunitinib | NR | 23.3 | 1.51 (0.837–2.72) | 0.159 |
IFN-α | 22.0 | 16.5 | 1.01 (0.619–1.66) | 0.961 | |
sVEGFR-3 | Sunitinib | NR | 23.3 | 1.68 (0.928–3.04) | 0.0738 |
IFN-α | 22.0 | 17.6 | 1.24 (0.757–2.04) | 0.388 | |
IL-8 | Sunitinib | NR | 23.3 | 1.37 (0.761–2.48) | 0.283 |
IFN-α | 22.0 | 12.9 | 1.52 (0.924–2.51) | 0.0897 |
CI confidence interval, HR hazard ratio, IL-8 interleukin-8, IFN-α interferon-alpha, NR not reached, PFS progression-free survival, OS overall survival, VEGF-A vascular endothelial growth factor A, VEGF-C vascular endothelial growth factor C, sVEGFR-3 soluble vascular endothelial growth factor receptor 3
aTotal N = 33 and N = 30 for each protein in the sunitinib and IFN-α arms, respectively, apart from IL-8, where total N = 31 and N = 29 in the sunitinib and IFN-α arms, respectively